Drug formulation developer CURE Pharmaceutical withdraws $12 million IPO

Shutterstock photo

CURE Pharmaceutical Holding, which is developing oral dissolving film formulations of existing drugs, withdrew its plans for an initial public offering on Friday. It had filed to raise $12 million by offering 2 million shares at a price range of $5 to $7.

The Oxnard, CA-based company was founded in 2011 and had planned to list on the Nasdaq under the symbol CURR. Network 1 Financial Securities was set to be the sole bookrunner on the deal.

The article Drug formulation developer CURE Pharmaceutical withdraws $12 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?